NCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT03841565 2022-06-15
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT04584307 2021-08-23
Immuno-POWER
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT04355039 2020-08-19
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT03657420 2019-08-14
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Withdrawn
NCT03227432 2018-08-14
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02578121 2017-01-23
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
University of Arkansas
Phase 2 Withdrawn